N/A
Completed N=35
Hyperglycemia and Mitochondrial Function in The Endothelium of Humans
Source: ClinicalTrials.gov NCT02682342 ↗Enrolled (actual)
35
Serious AEs
0.0%
Results posted
Jan 2025
Primary outcomePrimary: Change in Mitochondrial Network Complexity of Endothelial Cells as Measured by Mitochondrial Network Fragment Ratio
Summary
In this study, the investigators will test the hypothesis that acute in vivo exposure to hyperglycemia increases mitochondrial network fragmentation and mitochondrial reactive oxygen species production (ROS) production in human arterial endothelial cells.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Mitochondrial Network Complexity of Endothelial Cells as Measured by Mitochondrial Network Fragment Ratio |
— | — |
Eligibility Criteria
Inclusion Criteria
- Adult age 21 to 70
- No evidence of metabolic syndrome or diabetes, hypertension (BP≥140/90), or high cholesterol (LDL≥160) at the time of screening.
Exclusion Criteria
- History of stroke, peripheral arterial disease, or coronary artery disease (as defined by the presence of at least one coronary stenosis ≥ 40% on angiography or by confirmed history of myocardial infarction by standard criteria).
- History of bleeding disorders.
- Evidence of other evident major illness including chronic renal insufficiency (plasma creatinine > 1.4 for women or 1.5 for men), liver disease (liver enzymes greater than 2.5 x normal), and cancer
- currently undergoing therapy or had therapy for cancer within 1 year of enrollment.
- Pregnancy as determined by urinary human chorionic gonadotropin beta test
- Thienopyridine, anti-thrombin/Xa, or warfarin therapy at time of screening
- On medication for cholesterol or blood pressure
Data sourced from ClinicalTrials.gov (NCT02682342). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.